CC BY-NC-ND 4.0 · Semin Liver Dis 2021; 41(04): 495-506
DOI: 10.1055/s-0041-1732319
Review Article

Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review

Xinpei Gu
1  Department of Human Anatomy, Shandong First Medical University and Shandong Academy of Medical Sciences, Taian, China
Qin Lu
2  Department of Prescription Science, School of Basic Medical Sciences, Hebei University of Chinese Medicine, Shijiazhuang, China
Chengcheng Zhang
3  Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Zhewei Tang
3  Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Liuxi Chu
4  Institute of Child Development and Education, School of Biological Sciences and Medical Engineering, Southeast University, Nanjing, China
› Author Affiliations
Funding National Natural Science Foundation of China (81904129), the College Student Innovation Funds Project for the Hebei University of Chinese Medicine (31800952, 202014432203), the Fundamental Research Funds for the Southeast University (3218006405, 2242019s10024) sponsored this study.


The human gut harbors a dense and highly diverse microbiota of approximately 1,000 bacterial species. The interaction between the host and gut bacteria strongly influences human health. Numerous evidence suggest that intestinal flora imbalance is closely associated with the development and treatment of liver diseases, including acute liver injury and chronic liver diseases (cirrhosis, autoimmune liver disease, and fatty liver). Therefore, regulating the gut microbiota is expected to be a new method for the adjuvant treatment of liver diseases. Fecal microbiota transplantation (FMT) is defined as the transplantation of gut microbiota from healthy donors to sick patients via the upper or lower gastrointestinal route to restore the normal intestinal balance. In this study, we briefly review the current research on the gut microbiota and its link to liver diseases and then summarize the evidence to elucidate the clinical application and development of FMT in liver disease treatment.

Authors' Contributions

X.G. and L.C. designed the concept of the study. Q.L., C.Z., and X.G. wrote the first draft of the manuscript. L.C. and Z.T. edited the subsequent versions of the manuscript.

Publication History

Publication Date:
14 July 2021 (online)

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA